Drug – bio-affecting and body treating compositions – Antigen – epitope – or other immunospecific immunoeffector – Bacterium or component thereof or substance produced by said...
Reexamination Certificate
2007-08-14
2007-08-14
Kam, Chih-Min (Department: 1656)
Drug, bio-affecting and body treating compositions
Antigen, epitope, or other immunospecific immunoeffector
Bacterium or component thereof or substance produced by said...
C424S239100, C424S009100, C514S002600, C514S012200, C530S350000, C435S252700
Reexamination Certificate
active
10666408
ABSTRACT:
Methods for treating fibromyalgia by administering a therapeutically effective amount of abotulinumtoxin to a patient with fibromyalgia.
REFERENCES:
patent: 5437291 (1995-08-01), Pasricha et al.
patent: 5707642 (1998-01-01), Yue
patent: 5714468 (1998-02-01), Binder
patent: 5766605 (1998-06-01), Sanders et al.
patent: 5863552 (1999-01-01), Yue
patent: 5962479 (1999-10-01), Chen
patent: 5989545 (1999-11-01), Foster et al.
patent: 6009875 (2000-01-01), Hubbard, Jr.
patent: 6063768 (2000-05-01), First
patent: 6113915 (2000-09-01), Aoki et al.
patent: 6136551 (2000-10-01), Aoki
patent: 6174880 (2001-01-01), Bernstein
patent: 6201022 (2001-03-01), Mease et al.
patent: 6623742 (2003-09-01), Voet
patent: WO94/15629 (1994-07-01), None
patent: WO95/17904 (1995-07-01), None
patent: WO99/03483 (1999-01-01), None
Paulson et al:Movement Disorders, 1996; 11(4): 459, Botulinum Toxin is Unsatisfactory Therapy for Fibromyalgia.
Giladi:Journal of Neurological Sciences, 1997; 152: 132-135, The Mechanism of action of Botulinum toxin type A in Focal dystonia is most probably through its dual effect in efferent ( motor ) and afferent pathways at the injected site.
Welch et al:Toxicon, 2000; 38: 245-258, Sensitivity of embryonic rat dorsal root ganglia neurons to Clostridium botulinum neurotoxins.
R. Staud et al:Pain, 2001; 91: 165-175, Abnormal sensitization summation of second pain ( wind-up ) in patients with fibromyalgia syndrome.
Jerome Groopman:The New Yorker, Nov. 13, 2001; 78-92, Hurting all over.
Freund et al:J Oral Maxillofac Surg, 1999; 57: 916-920, The Use of Botulinum Toxin for the Treatment of Temporomandibular Disorders: Preliminary Findings.
Keller et al:The Journal of Biological Chemistry, 2001; 276( No. 16): 13476-13482, The Role of the Synaptic Protein SNAP-25 in the Potency of Botulinum Neurotoxin Type A.
Binder et al:Movement Disorders, 13 (Suppl 2): 241:1998, Botulinum Toxin Type A (BTX).
Siberstein et al:Headache, 40;445-450:2000, Botulinum Toxin Type A as a Migraine Preventive Treatment.
Reija:Eur. Journal of Neurology, 4 (Suppl 2) S71-73: 1997, Treatment of Tension-Type Headache by Local injection of Botulinum Toxin.
Cheshire et al:Pain, 59:65-69:1994, Botulinum Toxin in the Treatment of Myofascial Pain Syndrome.
Filippi et al:Acta Otolaryngologica113;400-404: 1993, Effects on Rat Jaw Muscle Spindles.
Nix et al:Neurology42;602-606 (1992).
Asherson, R.A., et al.,The Use of Botulinum Toxin-A in the Treatment of Patients with Fibromyalgia, The Journal of Rheumatology 2001: Jul. 28 : 7 p. 1740.
Raj:Pain Digest, 1998: 6: 357-363, Diagnosis and Management of Fibromyalgia and Myofascial Pain Syndrome.
Wiegand et al:Naunyn-Schmiedeberg's Arch. Pharmacol, 1976; 292: 161-165, I-Labeled Botulinum A Neurotoxin: Pharmacokinetics in Cats after intramuscular injection.
Haberman:Naunyn-Schmiedeberg's Arch. Pharmacol, 1974; 281: 47-56, I-Labeled Neurotoxin from Clostridium Botulinum A: Preapration, Binding to Synaptosomes and Ascent to the Spinal Cord.
Mantyh:Annals New York Academy of Science; Part V: vol. 632 263-270, Substance P and the Inflammatory and Immune Response, (1991).
Spiegelman & Pull:Annals New York Academy of Science; vol. 632 220-228, Substance P Actions on Sensory Neurons, (1991).
M.K. Childers et al:Journal of Back and Musculoskeletal Rehablitation, 1998; 10: 89-96, Treatment of painful muscle syndromes with Botulinum toxin: A review.
Allergan Inc.
Donovan Stephen
Kam Chih-Min
Nassif Claude L.
LandOfFree
Botulinum toxin therapy for fibromyalgia does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Botulinum toxin therapy for fibromyalgia, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Botulinum toxin therapy for fibromyalgia will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3859474